Welcome
Support Centre
06 January 2009 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A randomised controlled trial of a patient-held quality of life record in patients with inoperable lung and oesophageal cancer
ISRCTN ISRCTN58789949
ClinicalTrials.gov identifier
Public title A randomised controlled trial of a patient-held quality of life record in patients with inoperable lung and oesophageal cancer
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis To determine if patient held Quality of Life (QoL) tools improve the quality of care and patient quality of life.
Ethics approval Approval given by Office of Resarch Ethics Committees Northern Ireland (ORECNI) on the 30th November 2004 (ref: 04/NIR01/77).
Study design A multi-centred randomised controlled trial.
Countries of recruitment United Kingdom
Disease/condition/study domain Lung and oesophageal cancer
Participants - inclusion criteria 1. Inoperable lung and oesophageal cancer
2. World Health Organisation (WHO) performance status of zero to two
3. No cognitive impairment
Participants - exclusion criteria 1. Surgically resectable patients
2. WHO performance status of 3+
3. Cognitively impaired patients
Anticipated start date 01/01/2005
Anticipated end date 01/01/2007
Status of trial Completed
Patient information material
Target number of participants 150
Interventions Patients receive a QoL diary which consists of a core questionnaire (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients [EORTC QLQ C-30]) with a Lung (LC-13) or Oesophageal (OES-18) cancer module, in the form of an A5 booklet, which they complete weekly. Patients are encouraged to share their diary with health professionals involved in their care.

The duration of treatment was four months, and at the end of this period outcomes were collected for both arms of the treatment, therefore there is no additional follow-up period for this trial.
Primary outcome measure(s) The primary outcome is QoL, measured through two questionnaires:
1. Functional Assessment of Cancer Therapy - General questionnaire (FACT-G) with lung and oesophageal modules, measured at the end of month two and month four following recruitment
2. Palliative care quality of life index, measured at the end of month two and month four following recruitment
Secondary outcome measure(s) Secondary outcomes include:
1. Indices of patient satisfaction, measured at the end of month two and month four following recruitment
2. Impact on carers, measured at the end of month two and month four following recruitment
3. Measures of communication, measured at the end of month two and month four following recruitment
4. Multi-disciplinary nature of patient management, measured at the end of month two and month four following recruitment
Sources of funding Research and Development Office of Northern Ireland (UK) (ref: EAT/2551/03)
Trial website
Publications
Contact name Mrs  Moyra  Mills
  Address Epidemiology and Public Health
Mulhouse Building
Royal Victoria Hospital
Grosvenor Road
  City/town Belfast
  Zip/Postcode BT12 6BJ
  Country United Kingdom
  Tel +44 (0)28 90635059
  Email mmills05@qub.ac.uk
Sponsor Queen's University Belfast (UK)
  Address University Road
  City/town Belfast
  Zip/Postcode BT7 1NN
  Country United Kingdom
  Tel +44 (0)28 90272568
  Fax +44 (0)28 90272570
  Email rrs@qub.ac.uk
  Sponsor website: http://www.qub.ac.uk
Date applied 01/06/2007
Last edited 25/06/2007
Date ISRCTN assigned 25/06/2007
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central